

Translational Studies of Protandim[®] as a Candidate Nutraceutical Approach to Treating
Ovarian Cancer

A THESIS
SUBMITTED TO THE FACULTY OF
MAYO CLINIC COLLEGE OF MEDICINE
MAYO GRADUATE SCHOOL

BY
Naiyarat Prasongsook, M.D.

IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
FOR THE DEGREE OF
MASTER'S IN BIOMEDICAL SCIENCES-
CLINICAL AND TRANSLATIONAL SCIENCE

March, 2014

UMI Number: 1555561

All rights reserved

INFORMATION TO ALL USERS

The quality of this reproduction is dependent upon the quality of the copy submitted.

In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion.



UMI 1555561

Published by ProQuest LLC (2014). Copyright in the Dissertation held by the Author.

Microform Edition © ProQuest LLC.

All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code



ProQuest LLC.
789 East Eisenhower Parkway
P.O. Box 1346
Ann Arbor, MI 48106 - 1346

© Naiyarat Prasongsook, March 2014

PREVIEW

Acknowledgements

I would like to thank all of the people who made this dissertation possible, starting with my mentor in the Division of Medical Oncology, Keith C. Bible, M.D., Ph.D.. Dr. Bible proved an excellent sounding board for me from the beginning of my thesis work, and steered me toward thinking about translational and clinical research initiatives directed toward the ultimate goal of improving therapies for patients afflicted with cancer, especially nutraceutical therapeutic approaches to ovarian cancer.

All thesis advisory committee members; Dr. Prema P. Peethambaram, Dr. Vijayalakshmi (Viji) Shridhar, and Dr. Vera J. Suman, thank you very much for teaching me how to meticulously execute the experiments and to critically evaluate my data. Special thanks for their time devoted to my lengthy thesis committee meetings and for their continued support in all my endeavors.

In addition, I would like to thank Dr. Vijayalakshmi (Viji) Shridhar for providing many ovarian cancer cell lines (SKOV3ip, SKOV3TR, A2780, C200, OV2008, C13) used in my studies of the cytotoxic effects and mechanism(s) of action of Protandim[®].

Furthermore, I would like to thank Ayoko Bossou, M.S. and Crescent Isham, B.S. for their mentorship and sage guidance, and advice related to my laboratory studies. It is no exaggeration to say that all experiments would not have been possible without their advise and encouragement.

Specifically, I would like to express my sincere gratitude to Dr. Thanyanan Reungwetwattana who encouraged me to further my education and experience this incredible journey at the Mayo Clinic. I gratefully thank her for her continued guidance and support in all my endeavors.

Lastly, I would like to thank you Phramongkutklao Hospital and the Royal Thai Army for their financial support throughout my time here.

This thesis was made possible by CTSA Grant Number **UL TROOO135** from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.

PREVIEW

Dedication

I would like to dedicate my thesis to my beloved parents, and my aunt.

PREVIEW

Abstract

Background and Rationale: Use of nutraceutical approaches are rapidly increasing in cancer patients. We encountered a recurrent ovarian cancer patient who incurred durable tumor regression and decreasing CA-125 coincident with initiation of the nutraceutical Protandim[®], a combination of five phytochemical extracts (ashwagandha, bacopa, green tea, milk thistle, turmeric). Preclinical studies were undertaken to investigate Protandim[®] and Protandim[®] constituent anticancer effects and underlying mechanism(s).

Methods: *In vitro* and *in vivo* ovarian cancer cell line models were used to assess Protandim[®] and Protandim[®] constituent effects. Colony forming assays, Hoechst nuclear and Trypan exclusion staining, immunoblotting, and flow cytometric methods were used to assess growth inhibitory, cytotoxic, apoptotic/necrotic effects as well as to preliminarily assess involved mechanism(s) of action. Combined synergistic/additive/antagonistic effects of Protandim[®] components were assessed by the methods of Chou and Talalay; an *ex vivo* myeloma patient model system was used to assess cancer selectivity. *In vivo* studies assessed Protandim[®] tolerability and toxicity over a wide oral dosage range.

Results: Anticancer effects of Protandim[®] and its constituent extracts were demonstrated, with induction of necrotic – not apoptotic - morphological cell death. *Ex vivo* assays demonstrated Protandim[®] to selectively kill freshly collected patient myeloma cells, relatively sparing paired patient normal bone marrow cells, indicating anticancer-selectivity. Immunoblotting and flow cytometric experiments indicated that Protandim[®] induced increased levels of cellular reactive oxygen species (ROS). Similar cytotoxic effects in wild-type- and Rho-MOLT4 cells (absence of mitochondria function) indicated non-mitochondrial mediated ROS induction by Protandim[®]. Assessment of the combined effects of Protandim[®] constituents primarily demonstrated antagonism or additivity. *In vivo* mouse studies demonstrated no Protandim[®] toxicities when compounded in diet during 43 days of feeding.

Conclusions: Protandim[®] and some of its ingredients (green tea and turmeric) have promising activity in ovarian cancer models, associated with induction of non-mitochondrial mediated-ROS and necrosis. Moreover, Protandim[®] is well-tolerated in mice, and has anti-cancer selectivity when assess in a myeloma/normal cell *ex vivo* model. Further investigations to more specifically assess molecular mechanism and *in vivo* efficacy are presently underway, in anticipation of eventual translation to therapeutic human clinical trials in ovarian cancer.

PREVIEW

Table of Contents

Acknowledgments.....	i
Dedications.....	iii
Abstract.....	iv
Table of contents.....	vi
List of tables.....	vii
List of figures.....	viii
List of abbreviations.....	xi
Chapter 1: Introduction.....	1
Patient-based Anecdotal Protandim [®] Experience.....	2
What is Protandim [®]	4
History of Protandim [®]	5
Summary of Published Protandim [®] Research.....	5
Oxidative Stress and Cancer.....	7
Nutraceutical Approach for Cancer Treatment.....	8
Chapter 2: Protandim [®] as a Candidate Nutraceutical Approach.....	13
to Treating Ovarian Cancer	
Introduction.....	14
Specific Aims and Hypothesis.....	15
Materials and Methods.....	16
Statistical Analysis.....	23
Results.....	24
Discussion.....	49
Limitations.....	62
Conclusions.....	65
Chapter 3: Future directions and Summary.....	67
Future directions.....	68
Summary.....	70
References.....	72

List of Tables

Table 1. Dose-effect relationship parameters for Protandim [®] and 43	43
turmeric in ovarian cancer model (SKOV3 cell line)	

PREVIEW

List of Figures

Figure 1. Computed tomography (CT) scan of the upper abdomen demonstrated response to Protandim [®] treatment in a recurrent fallopian tube cancer patient	3
Figure 2. Changes of the serum tumor marker (CA-125) before and after taking Protandim [®]	3
Figure 3A-E. Five herbals ingredient in Protandim [®]	4
Figure 4. Line drawings and descriptions of body condition scoring (BCS)	22
Figure 5A. Protandim [®] reduced colony formation in multiple ovarian cancer cell lines (24 h Protandim [®] exposures)	25
Figure 5B. Cisplatin significantly reduced colony formation in platin-sensitive ovarian cancer cell lines	25
Figure 6. Protandim [®] reduced colony formation in both paclitaxel-sensitive and paclitaxel-resistant ovarian cancer cell lines (24 h exposures).	26
Figure 7. Paclitaxel significantly reduced colony formation in paclitaxel-sensitive ovarian cancer cell line.	26
Figure 8. Colony forming assay showed anticancer effect of Protandim [®] constituents (turmeric, green tea) at 24 hours versus continuous exposures on SKOV3 ovarian cancer cells.	28
Figure 9. Colony forming assay showed anticancer effect of Protandim [®] constituents (Milk thistle, Ashwagandha, and Bacopa) at 24 hours versus continuous exposures on SKOV3 cells.	28
Figure10. Colony forming assay showed relationship between anticancer effects and concentration-adjusted amounts of each extract contained in Protandim [®] on SKOV cells.	29
Figure 11A. Morphology of untreated SKOV3 cells by fluorescence microscopy using Hoechst 33342 staining.	30
Figure 11B. Morphology of treated SKOV3 cells with 100 µg/mL Protandim [®] by fluorescence microscopy using Hoechst 33342 staining.	30

Figure 12. Quantitative assessment for cell death and apoptotic cells after 24 hours treatment of SKOV3 cells with 100 µg/mL Protandim®	31
Figure 13A-C. Levels of HO-1 and actin were assessed in SKOV3 PEO1 and PEO4 cancer cells by using immunoblotting.	32
Figure 14A. FACS analyses assessing the proportion of ROS expression among SKOV3 cells treated with DMSO, Protandim®, Bixin, Chaetocin, and Tert-butyl hydroperoxide using DHE and CM-H ₂ DCFDA ROS probes.	34
Figure 14B. FACS analyses assessing the proportion of ROS expression among SKOV3 cells treated with Protandim® using DHE probe.	34
Figure 14C-F. FACS assessment of ROS levels in response to increasing concentrations of Protandim® constituents (Ashwagandha, Bacopa, Green tea, and Milk thistle) using DHE probe.	35
Figure 14G. FACS assessment of ROS levels in response to increasing concentrations of turmeric using DHE probe.	35
Figure 14H. ROS induction of SKOV3 cells in response to treatment with 25 µg/mL of Protandim® and Protandim® constituent ingredient extracts using DHE as fluorescent FACS probe.	36
Figure 15A-C. Protandim®, curcumin, and chaetocin –induced cytotoxicity (assessed by trypan blue exclusion assay, 24 hours exposures) is unaltered in MOLT-4 rho cells lacking respiratory functional mitochondria.	38
Figure 15D. Antimycin-induced cytotoxicity (assessed by trypan blue exclusion assay, 24 hours exposures) was attenuated in MOLT-4 rho cells lacking respiratory functional mitochondria.	38
Figure 16A-C. Protandim® selectively kills collected and sorted <i>ex vivo</i> –treated patient myeloma cells (CD138 +) cells assessed by counting trypan blue on day 1- day 3.	40
Figure 17A-D. Combined effects of green tea and turmeric with respect to Protandim® anticancer activity assessed in SKOV3 cell line.	42

Figure 18. Median dose effect plot for Protandim [®] , turmeric, and its combination was at (a 3.75 : 1 ratio for Protandim [®] : turmeric).	44
Figure 19A-E. <i>in vivo</i> study showed the percentage of body weight for 5 groups of mice during entire period of experiment (43 days).	46
Figure 20. One-way analysis demonstrated comparisons the average percentage of weight change among those mice in 5 groups during whole period of experiment.	47
Figure 21. Signaling components potentially involved in programmed necrosis	51
Figure22. The strategic approach to targeting cancer cells via ROS-mediated mechanisms.	54
Figure23. Major sites of cellular reactive oxygen species (ROS) generation	55
Figure24. NADPH oxidase (NOX) complex generated ROS	57

List of abbreviations

A2780 cell line, ovarian cancer cell line
Akt, protein kinase B (serine/threonine-specific protein kinase)
ALT, alanine- amino-transferase
ANOVA, analysis of variance
AST, aspartate-amino-transferase
BCA, bicinchoninic acid assay
BCS, body condition scoring
BUN, blood urea nitrogen
C13, ovarian cancer cell line with platin-resistant
C200, ovarian cancer cell line
CA-125, cancer antigen 125, or carcinoma antigen 125, or carbohydrate antigen 125
CD138, Syndecan 1; a protein which in human is encoded by the syndecan (SDC) 1 gene
CI, Combination Index
CMH2DCFDA, 5,6-chloromethyl-20, 70-dichlorodihydrofluorescein diacetate
Cr, creatinine
CT, computed tomography
D, dose
DHE, dihydroethidium
Dm, median dose effect
DMEM, Dulbecco's Modified Eagle's Medium
DMSO, dimethyl sulfoxide
DNA, deoxyribonucleic acid
DRI, dose reduction index
Duox, dual oxidases
ECs, endothelia cells
ED50, effective dose 50; minimum effective dose for 50% of the population
EGCG, (-)-epigallocatechin-3-gallate
ER, endoplasmic reticulum

fa, affected fraction
FACS, Fluorescence-Activated Cell Sorting analysis
FAD, Flavin Adenine Dinucleotide
FasR, Fas receptor
fu, unaffected fraction
FY, fiscal year
G1, gap 1
G2, gap 2
GCLC, glutamate-cysteine ligase catalytic
GCLM, glutamate-cysteine ligase modifier
GST, glutathione S-transferase
H₂O₂, hydrogen peroxide
HCAEC, human coronary artery endothelial cells
HO-1, heme oxidase 1
IACUC, Institutional Animal Care and Use Committee
IC₅₀, inhibit cellular proliferation by 50%
ip, intraperitoneal
IRB, international review board
m, the slope of the median-effect plot
M, mitosis
MAb, monoclonal antibody
MEM, Minimum Essential Medium
Mito-ETC, mitochondrial electron transport chain
NADPH oxidases (NOX), Nicotinamide Adenine Dinucleotide Phosphate Oxidase
NFE2L2 (Nrf2), Nuclear factor (erythroid-derived 2)-like 2
NOXO, NADPH oxidase organizer
Nqo1, nicotinamide adenine dinucleotide phosphate quinone oxidoreductase 1
O₂^{•-}, superoxide anion
OV (202, 2008) cell line, ovarian cancer cell line

p22^{phox}, Neutrophil cytochrome b 22 kilo Dalton polypeptide, alpha polypeptide type of cytochrome b-245

p38MAPK, p38 mitogen-activated protein kinase

p40^{phox}, 40 kilo Dalton cytosolic subunit of neutrophil cytosolic factor 4

p47^{phox}, 47 kilo Dalton cytosolic subunit of neutrophil NADPH oxidase (Neutrophil cytosolic factor 1)

p53, phosphoprotein p53, or cellular tumor antigen p53, or tumor suppressor p53

p67^{phox}, 67 kilo Dalton cytosolic subunit of the multi-protein complex (Neutrophil cytosolic factor 2)

PARP1, poly (adenosine diphosphate ribose) polymerase-1

PBS, phosphate-buffered saline

PCD, program cell death

PEO cell line, estrogen receptor positive Human ovarian cancer cell line

PI3-kinase, phosphatidylinositide 3-kinase

PKC δ , protein kinase C delta type

platin, cisplatin

r, the correlation coefficient

Rac GTPases, Rho family of GTPases; a family of small (~21 kilo Dalton) signaling G protein and is a subfamily of the Ras superfamily

Rho-MOLT4 cell line, acute lymphoblastic leukemia cell line with mitochondrial respiratory chain nonfunctioning

RIP, receptor interacting protein

RMPI media, Roswell Park Memorial Institute media

ROS, reactive oxygen species

S, synthesis

SD, standard deviation

SDS, sodium dodecyl sulfate

SE, standard error

SEM, standard error of the mean

SKOV3 cell line, Sloan-Kettering HER2 3+ Ovarian Cancer cell line

SKOV3TR cell line, Sloan-Kettering HER2 3+ Ovarian Cancer cell line with Taxol resistant

SOD, superoxide dismutase

T1, the first stage of translational research

t-BHP, tert-butyl hydroperoxide

TNFR, tumor necrosis factor receptor

UGT, uridine diphosphate- glucuronosyltransferase

VEGF, vascular epithelial growth factor

WT-MOLT4 cell line, wild type of acute lymphoblastic leukemia cell line

PREVIEW

Chapter 1:

Introduction

PREVIEW

Introduction

Epithelial ovarian cancer is the deadliest of all cancers of the female reproductive system and the fifth most common cause of cancer mortality in women (1). Every 24 minutes marks another diagnosis of ovarian cancer in the United States; a woman's lifetime risk of developing invasive ovarian cancer is 1 in 72 (1-3). In 2013, the American Cancer Society estimates that 22,240 new cases will be diagnosed and an 14,030 women will die of ovarian cancer in the United States alone (1). In spite of the National Cancer Institute's (NCI) investment of \$110.8 million in fiscal year (FY) 2011 for ovarian cancer research (4-5), treatment outcomes for ovarian cancer remain poor. In particular, overall 5-year survival is < 35% and "cure" rates have unfortunately not substantively improved in decades. Consequently, there is need for additional therapeutic innovation to further improve not only response durations and "cure" rates, but also to attain lessened adverse effects.

Patient-based Anecdotal Protandim[®] Experience

The genesis of this study stems from a 64 year-old women diagnosed with recurrent fallopian tube carcinoma with peritoneal metastasis and a rising of the serum tumor marker, CA-125. She declined standard salvage chemotherapy, and instead, on her own volition, initiated nutraceutical therapy with Protandim[®]. Interestingly, this patient incurred durable clinical improvement in terms reduction in the size of her peritoneal lesions, and declining CA-125 without apparent toxicity. This anecdotal experience triggered our interest in assessing the anticancer effects of Protandim[®] and raised the question of whether it might have clinical application beyond this anecdotal experience.




Figure 1: A 64 year-old female patient, treated for peritoneal metastasis: A and C: CT upper abdomen before taking Protandim[®] that showed 2 areas of peritoneal fluid/metastasis; B and D: CT upper abdomen 12 months after taking Protandim[®] that the two areas were significantly decreased in size (near complete response).




Figure 2. Changes of the serum CA-125 before and after taking Protandim[®]. CA-125 declined after Protandim[®] use for 3 months, attaining normal range (< 35 unit/milliliter) at 6 months of Protandim[®] use.